United Therapeutics (UTHR) Research & Development (2016 - 2026)
United Therapeutics' Research & Development history spans 17 years, with the latest figure at $139.5 million for Q4 2025.
- On a quarterly basis, Research & Development rose 4.26% to $139.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $550.0 million, a 14.35% increase, with the full-year FY2025 number at $550.0 million, up 14.35% from a year prior.
- Research & Development hit $139.5 million in Q4 2025 for United Therapeutics, up from $127.5 million in the prior quarter.
- Over the last five years, Research & Development for UTHR hit a ceiling of $303.7 million in Q1 2021 and a floor of $66.1 million in Q3 2022.
- Historically, Research & Development has averaged $115.1 million across 5 years, with a median of $98.7 million in 2022.
- Biggest five-year swings in Research & Development: soared 314.89% in 2021 and later tumbled 77.28% in 2022.
- Tracing UTHR's Research & Development over 5 years: stood at $82.9 million in 2021, then increased by 13.27% to $93.9 million in 2022, then surged by 61.24% to $151.4 million in 2023, then decreased by 11.62% to $133.8 million in 2024, then rose by 4.26% to $139.5 million in 2025.
- Business Quant data shows Research & Development for UTHR at $139.5 million in Q4 2025, $127.5 million in Q3 2025, and $134.0 million in Q2 2025.